Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PINK /
  3. ORYZF.PINK

Oryzon Genomics S.A (ORYZF PINK) stock market data APIs

$1.41 0(0%) as of July 26, 2024
Price chart is built with Anychart

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

Oryzon Genomics S.A Financial Data Overview

1.41
1.41
-
1.41
1.41
1.41-2.45
136 M
63 775 K
16 615 K
0.634
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ORYZF',
Type: 'Common Stock',
Name: 'Oryzon Genomics S.A',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00R4RWLB2',
ISIN: NULL,
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Oryzon Genomics S.A Fundamental Data is available in our Financial Data APIs

  • Net Revenue 16 615 K
  • EBITDA -20 715 964
  • Earnings Per Share -0.05
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Oryzon Genomics S.A Earnings via APIs

  • Latest Release 2024-07-24
  • EPS/Forecast NaN

Get Oryzon Genomics S.A End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Oryzon Genomics S.A latest news via APIs

Oryzon Announces Completed Patient Recruitment in the PORTICO Phase IIb Trial of vafidemstat in Borderline Personality Disorder

Oryzon Genomics, S.A. Full recruitment secures the target number of completer patients Multiple primary endpoints include reduction in agitation and aggression and overall disease improvement Toplin...

ORYZON Reports Financial Results and Corporate Updates for Half-Year Ending June 30, 2023

Oryzon Genomics, S.A. Positive aggregate safety data from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD), consistent with safety data from seven completed clinical tri...
Do you have any questions?
support@eodhistoricaldata.com